Previsioni

Il prezzo obiettivo medio degli analisti è 4,51 € (+0,45%). La mediana è 4,51 € (+0,45%).

Acquista	5
Mantieni	5
Vendi	0

Notizie Vai al feed delle notizie

Generation Bio: CEO Geoff McDonough resigns and becomes chairman of the board

Generation Bio announced that CEO and president Dr. Geoff McDonough will resign effective October 31, 2025, and will move into the role of chairman of the board. Chief Legal Officer Yalonda Howze will serve as interim CEO and president. The company plans a comprehensive restructuring with a workforce reduction of around 90% by the end of October 2025 and, with support from TD Cowen, is reviewing strategic alternatives such as acquisitions, mergers or asset sales. Analysts adjusted their ratings and price targets following the reorganization; financially, Generation Bio has more cash than debt and a current ratio of 7.5, but shows a high cash burn. » Altro su de.investing.com
Generation Bio reports 81% revenue drop and EPS of -$3.12

Generation Bio reported earnings per share of -$3.12 and revenue of $0.8 million for the quarter ended June 30, 2025. Revenue thus declined 81.17% compared with the same quarter last year ($4.1 million). » Altro su finanzen.net

Dati finanziari dell'azienda

Nell'ultimo trimestre, GENERATION BIO CO.-,0001 ha registrato ricavi pari a 1,36 Mln € e un utile netto di -4,7 Mln €

(EUR)	set 2025	YoY
Ricavi	1,36 Mln	-
Utile lordo	161,9K	-
Utile netto	-4,7 Mln	-
EBITDA	-3,51 Mln	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	30,9 Mln €
Numero di azioni	6,74 Mln
Massimo/minimo a 52 settimane	6,45 € - 2,58 €
Dividendi	No
Beta	2,01
Rapporto P/E	-0,87
Rapporto PEG	-0,01
Rapporto P/B	0,71
Rapporto P/S	3,25

Profilo aziendale

Generation Bio Co. ist ein Unternehmen für genetische Arzneimittel und entwickelt Therapien für die Behandlung seltener und weit verbreiteter Krankheiten. Das Unternehmen bietet ein Portfolio von Programmen an, darunter Programme für seltene und weit verbreitete Erkrankungen der Leber und der Netzhaut. Weitere Schwerpunkte sind Erkrankungen der Skelettmuskulatur, des zentralen Nervensystems und der Onkologie. Das Unternehmen war früher als Torus Therapeutics, Inc. bekannt und änderte im November 2017 seinen Namen in Generation Bio Co. um. Generation Bio Co. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.

Nome	GENERATION BIO CO.-,0001
CEO	Yalonda Howze
Sede centrale	Cambridge, ma Stati Uniti
Sito web	generationbio.com
Settore	Materiali
Industria	Prodotti chimici
Quotazione in borsa	12/06/2020
Dipendenti	115